ROCHESTER, N.Y.--(BUSINESS WIRE)--July 25, 2006--Biophan Technologies, Inc. (OTCBB: BIPH; FWB: BTN), a developer of next-generation medical technology, today announced the formation of a Scientific Advisory Board to oversee the development, clinical evaluation, and commercialization of MYO-VAD, a novel cardiac assist device designed to treat many types of heart failure. Biophan Technologies, Inc. holds a 42% interest in MYOTECH with rights to acquire a majority position, and is leading MYOTECH's business development activities.
